| Title |
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
|
|---|---|
| Published in |
Breast cancer targets and therapy, April 2012
|
| DOI | 10.2147/bctt.s29996 |
| Pubmed ID | |
| Authors |
Sara A Hurvitz, Reva Kakkar |
| Abstract |
This review aims to present the preclinical and clinical data regarding efficacy and safety of lapatinib alone and in combination with other agents in the treatment of human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 22% |
| Student > Bachelor | 6 | 19% |
| Student > Master | 5 | 16% |
| Student > Ph. D. Student | 4 | 13% |
| Student > Postgraduate | 3 | 9% |
| Other | 3 | 9% |
| Unknown | 4 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 28% |
| Medicine and Dentistry | 6 | 19% |
| Agricultural and Biological Sciences | 5 | 16% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Psychology | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 4 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2012.
All research outputs
#20,656,820
of 25,374,917 outputs
Outputs from Breast cancer targets and therapy
#233
of 324 outputs
Outputs of similar age
#135,133
of 173,050 outputs
Outputs of similar age from Breast cancer targets and therapy
#4
of 5 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 324 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,050 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.